Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 8
Navigating Treatment Strategies for Advanced Cervical Cancer: Localized Therapy, KEYNOTE-A18 Trial Data, and Frontline Approaches
Panelists discuss key findings from the KEYNOTE-A18 trial, which evaluated pembrolizumab in combination with chemoradiotherapy for high-risk locally advanced cervical cancer, highlighting the implications for treatment approaches in this patient population.
Video content above is prompted by the following:
- Briefly review the available treatment options for advanced cervical cancer.
- In which patients may you opt for localized therapy? What is your preferred treatment strategy, and what factors influence your treatment decision?
- Briefly comment on key findings, including overall survival data from the KEYNOTE-A18 trial, evaluating pembrolizumab + chemoradiotherapy in high-risk locally advanced cervical cancer.
- What implications do these findings have, and what impact may they have on your treatment approach for high-risk cervical cancer?
- In which patients may you forgo localized therapy? What is your preferred frontline treatment approach, and why?
- What is your next-line treatment strategy for patients who experience disease relapse on frontline therapy?
Related Content:
